drugset / Trial / NCT04172597
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
Timeline
- Start
- 2019-12-23
- Primary completion
- 2022-03-29
- Completion
- 2022-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Poziotinib | Small molecule | 8 mg | Oral |
| Background | Loperamide | Small molecule | — | — |